Piramal Pharma Ltd Submits FY26 BRSR Report
Piramal Pharma Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-26, along with an Independent Auditor’s Limited Assurance Report from DNV Business Assurance India Pvt Ltd. The report details the company's corporate identity, registered and corporate office addresses, financial year of reporting (April 1, 2025, to March 31, 2026), and stock exchange listings (NSE and BSE). It covers business activities contributing 100% to turnover, primarily pharmaceuticals manufacturing. The company operates 91 plants and 33 offices nationally, and 7 plants and 19 offices internationally, serving over 100 countries. Exports constitute 72.78% of total turnover. The report also includes employee data, with a total of 6,774 employees and 3,666 workers, and highlights the participation of women in leadership roles, with 30% on the Board of Directors and 50% in Key Management Personnel.
Key Highlights
- Piramal Pharma Ltd filed its FY26 BRSR and assurance report.
- Reporting covers pharmaceuticals manufacturing, 100% of turnover.
- Exports contribute significantly at 72.78% of total turnover.
- Company operates 91 plants and 33 offices nationally.
- Women hold 30% of Board seats and 50% of KMP positions.
Price Impact
More from PPLPHARMA